Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020231976 - TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFV600E COLORECTAL CANCER

Publication Number WO/2020/231976
Publication Date 19.11.2020
International Application No. PCT/US2020/032445
International Filing Date 12.05.2020
IPC
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/5377 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • ELI LILLY AND COMPANY [US]/[US]
Inventors
  • BHAGWAT, Shripad Venkatraman
  • JOSEPH, Sajan
  • TIU, Ramon Velasquez
Agents
  • ASAM, Michael R.
  • MCGRAW, Elizabeth A.
Priority Data
62/848,84116.05.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFV600E COLORECTAL CANCER
(FR) TRIPLE ASSOCIATION D'UN INHIBITEUR D'ERK1/2, D'UN INHIBITEUR DE BRAF ET D'UN INHIBITEUR DE L'EGFR, DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DU CANCER COLORECTAL POSITIF POUR LA MUTATION V600E DE BRAF
Abstract
(EN)
The present invention relates to a combination of an ERK1/2 inhibitor, 6,6- dimethyl-2-{2-[(l-methyl-lH-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4- yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, with encorafenib, or a pharmaceutically acceptable salt thereof, and cetuximab and to methods of using these combinations to treat certain disorders, such as colorectal cancer.
(FR)
La présente invention concerne une association d'un inhibiteur de ERK1/2, le 6,6-diméthyl-2-{2-[(l-méthyl-lH-pyrazol-5-yl)amino]pyrimidine-4-yl}-5-[2-(morpholine-4-yl)éthyl]-5,6-dihydro-4H-thiéno[2,3-c]pyrrol-4-one, ou un sel pharmaceutiquement acceptable de celui-ci, de corafénib, ou un sel pharmaceutiquement acceptable de celui-ci, et de cétuximab, ainsi que des méthodes d'utilisation de ces associations pour traiter certaines pathologies, telles que le cancer colorectal.
Latest bibliographic data on file with the International Bureau